Senzime is a leading global medical device company, developing precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Senzimes cutting-edge solutions TetraGraph and ExSpiron 2Xi are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory functions during and after surgery. With their dedicated team and strong partnerships, they are on a global mission to safeguard every patient's journey, from anesthesia to recovery. Established in 1999, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF).